<DOC>
	<DOCNO>NCT00834288</DOCNO>
	<brief_summary>The purpose study compare pharmacokinetic profile steady-state test product , Tramadol HCl Once-A-Day ( OAD ) 200 mg tablet reference product , Tramadol HCl 50 mg ( IR ) tablet ( Ortho-McNeil UltramÂ® ) . For purpose , extent absorption tramadol formation O-desmethyltramadol ( measure systemic exposure ) multiple administration 50 mg 6-hourly 07:30 , 13:30 , 19:30 01:30 ( reference product ) 200 mg 24-hourly 07:30 ( test product ) , compare .</brief_summary>
	<brief_title>A Study Compare Bioavailability Two Tramadol Hydrochloride Tablet Products ( 50 mg 200 mg , Respectively ) Steady-state Under Fasting Conditions</brief_title>
	<detailed_description />
	<mesh_term>Tramadol</mesh_term>
	<criteria>Healthy , nonsmoking , male female subject age 18 55 year ( inclusive ) . Body mass within 10 % ideal mass relation height age , accord BMI Body mass le 70 kg . Findings within range clinical acceptability medical history physical examination , laboratory result `` normal range '' relevant laboratory test ( unless clinical investigator considers deviation irrelevant purpose study ) . Normal ECG vital sign , abnormality clinical investigator consider disqualification participation study Willingness undergo prestudy physical examination pre poststudy laboratory investigation . Ability comprehend willingness sign statement Informed Consent ( screen phaserelated procedure ) Nonsmokers past smoker stop smoke least three month enter study For female , follow condition meet : postmenopausal least two year , surgically sterilize , childbearing potential , follow condition meet : normal menstrual flow within one month study entry , negative urine pregnancy test screen Day 1 study period . If result either test positive , subject would exclude study receive study medication . agree use accept method contraception . The subject agree continue method throughout study . Hormonal contraceptives allow . Evidence psychiatric disorder , antagonistic personality , poor motivation , emotional intellectual problem likely limit validity consent participate study limit ability comply protocol requirement . History , current compulsive alcohol abuse ( &gt; 10 drink weekly ) , regular exposure substance abuse . Use medication , prescribed overthecounter , within 2 week prior first administration study medication except would affect outcome study opinion clinical investigator . Use hormonal contraceptive agent female allow . Participation another study experimental drug within 8 week first administration study medication . Treatment within previous 3 month drug welldefined potential adversely affect major organ system evidence effect . Major illness 3 month commencement screening period . History hypersensitivity study drug relate drug . History bronchial asthma . History epilepsy . Relevant history laboratory clinical finding indicative acute chronic disease , likely influence study outcome . Donation loss blood equal exceed 500 ml 8 week first administration study medication . Diagnosis hypotension make screening period . Diagnosis hypertension make screening period current diagnosis hypertension . Resting pulse &gt; 100 beat per minute &lt; 45 beat per minute screen period , either supine standing . Positive test hepatitis B antigen . Significant liver disease , define active hepatitis elevate liver enzymes ( e.g. , AST , ALT ) &gt; 3 time upper boundary normal range . Positive urine screen drug abuse . Positive urine screen tobacco use . History marijuana , barbiturate , amphetamine , narcotic abuse within 12 month prior study start . Previous participation tramadol study . pregnancy lactation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Healthy subject</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Bioavailability</keyword>
</DOC>